These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17278963)

  • 1. Slowing arterial aging: how far have we progressed?
    Scuteri A
    J Hypertens; 2007 Mar; 25(3):509-10. PubMed ID: 17278963
    [No Abstract]   [Full Text] [Related]  

  • 2. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
    Zieman SJ; Melenovsky V; Clattenburg L; Corretti MC; Capriotti A; Gerstenblith G; Kass DA
    J Hypertens; 2007 Mar; 25(3):577-83. PubMed ID: 17278974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes].
    Zhong W; Wang LL; Cui H; Li S
    Yao Xue Xue Bao; 2005 Jan; 40(1):91-6. PubMed ID: 15881334
    [No Abstract]   [Full Text] [Related]  

  • 4. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
    Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S
    Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension and peripheral arterial disease.
    Bennett PC; Silverman S; Gill P
    J Hum Hypertens; 2009 Mar; 23(3):213-5. PubMed ID: 18923435
    [No Abstract]   [Full Text] [Related]  

  • 6. Keeping the pressure down in patients with type 2 diabetes and peripheral artery disease.
    SoRelle R
    Circulation; 2003 Feb; 107(5):E9008-9. PubMed ID: 12578895
    [No Abstract]   [Full Text] [Related]  

  • 7. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.
    Asif M; Egan J; Vasan S; Jyothirmayi GN; Masurekar MR; Lopez S; Williams C; Torres RL; Wagle D; Ulrich P; Cerami A; Brines M; Regan TJ
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2809-13. PubMed ID: 10706607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys.
    Vaitkevicius PV; Lane M; Spurgeon H; Ingram DK; Roth GS; Egan JJ; Vasan S; Wagle DR; Ulrich P; Brines M; Wuerth JP; Cerami A; Lakatta EG
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1171-5. PubMed ID: 11158613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats.
    Chang KC; Hsu KL; Chou TF; Lo HM; Tseng YZ
    Br J Pharmacol; 2004 Aug; 142(7):1099-104. PubMed ID: 15249427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [OPB-9195].
    Takeuchi M; Yamagishi S; Makita Z
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():606-10. PubMed ID: 12387058
    [No Abstract]   [Full Text] [Related]  

  • 11. Getting better without AGE: new insights into the diabetic heart.
    Kass DA
    Circ Res; 2003 Apr; 92(7):704-6. PubMed ID: 12702639
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?
    Singer DR; Kite A
    Eur J Vasc Endovasc Surg; 2008 Jun; 35(6):701-8. PubMed ID: 18375152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction.
    Aronson D
    Br J Pharmacol; 2004 Aug; 142(7):1055-8. PubMed ID: 15237100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
    Candido R; Forbes JM; Thomas MC; Thallas V; Dean RG; Burns WC; Tikellis C; Ritchie RH; Twigg SM; Cooper ME; Burrell LM
    Circ Res; 2003 Apr; 92(7):785-92. PubMed ID: 12623881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral vascular disease and hypertension: a forgotten association?
    Makin A; Lip GY; Silverman S; Beevers DG
    J Hum Hypertens; 2001 Jul; 15(7):447-54. PubMed ID: 11464253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to the seventh international workshop on structure and function of the vascular system.
    Struijker-Boudier HA; Blacher J; Lévy BI; Safar ME
    Hypertension; 2009 Aug; 54(2):373-4. PubMed ID: 19597032
    [No Abstract]   [Full Text] [Related]  

  • 17. Peripheral arterial disease and isolated systolic hypertension: the ATTEST study.
    Safar ME; Priollet P; Luizy F; Mourad JJ; Cacoub P; Levesque H; Benelbaz J; Michon P; Herrmann MA; Blacher J
    J Hum Hypertens; 2009 Mar; 23(3):182-7. PubMed ID: 18830251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases.
    Park K; Itoh H; Yamahara K; Sone M; Miyashita K; Oyamada N; Sawada N; Taura D; Inuzuka M; Sonoyama T; Tsujimoto H; Fukunaga Y; Tamura N; Nakao K
    Endocrinology; 2008 Feb; 149(2):483-91. PubMed ID: 17991722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological potential for reversing the ill effects of ageing and of arterial hypertension on central aortic systolic pressure.
    Kelly RP
    J Hypertens Suppl; 1992 Aug; 10(6):S97-100. PubMed ID: 1432338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease.
    Mechtouff L; Touzé E; Steg PG; Ohman EM; Goto S; Hirsch AT; Röther J; Aichner FT; Weimar C; Bhatt DL; Alberts MJ; Mas JL;
    J Intern Med; 2010 Jun; 267(6):621-33. PubMed ID: 20210837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.